-
STAT+: Its founder hopes to reverse aging, but first Tally Health wants to test how fast your biological clock ticks
STAT+: Its founder hopes to reverse aging, but first Tally Health wants to test how fast your biological clock ticks To be a student in David Sinclair’s Harvard University lab is to be a time traveler. The genetics professor has dedicated his career to understanding the processes that define getting older, and more recently, how…
-
STAT+: Once high-flying Rubius to shut down. Its flameout is a lesson for biotech
STAT+: Once high-flying Rubius to shut down. Its flameout is a lesson for biotech Rubius Therapeutics went public in 2018 at a $2 billion valuation — the largest biotech stock market debut at that time. On Wednesday, the company — battered down to a market value of $15 million — said it was shutting down…
-
STAT+: First non-immunosuppressive drug approved for a rare and deadly kidney disease
STAT+: First non-immunosuppressive drug approved for a rare and deadly kidney disease SAN DIEGO — Travere Therapeutics, a biotech focused both on treating rare diseases and distancing itself from controversial founder Martin Shkreli, on Friday won accelerated approval for a drug that treats IgA nephropathy, a rare and deadly autoimmune disease that attacks the kidneys…
-
STAT+: FDA approves first treatment for leading cause of blindness in older people
STAT+: FDA approves first treatment for leading cause of blindness in older people The Food and Drug Administration approved on Friday the first treatment for geographic atrophy, a progressive eye disease and a leading cause of blindness in older people. The new drug, called Syfovre, is made by Apellis Pharmaceuticals. Continue to STAT+ to read…
-
STAT+: Pfizer scraps half of participants in Lyme disease drug trial due to quality issues
STAT+: Pfizer scraps half of participants in Lyme disease drug trial due to quality issues Pfizer and partner Valneva are scrapping data from roughly half of the participants in a Phase 3 trial of a Lyme disease vaccine candidate after uncovering quality issues with a third-party clinical trial operator. The companies disclosed Friday that violations…
-
STAT+: Novartis CEO Vas Narasimhan talks PhRMA, gene therapy, and much more
STAT+: Novartis CEO Vas Narasimhan talks PhRMA, gene therapy, and much more Last week there was a change at the top of PhRMA, the trade group representing the drug industry. Novartis CEO Vas Narasimhan became the chair of the board of directors. Narasimhan has been CEO of Novartis since 2018. He sat down with STAT…
-
STAT+: Ginkgo chief Jason Kelly is chairing a federal biotech advisory group. Is that a conflict of interest?
STAT+: Ginkgo chief Jason Kelly is chairing a federal biotech advisory group. Is that a conflict of interest? Ginkgo Bioworks CEO Jason Kelly has spent much of the last decade talking to almost anyone who will listen — investors, journalists, TV presenters, congressional committees — about the importance of biotechnology to the future of, well,…
Got any book recommendations?